Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Albiruni R.A. Razak"'
Autor:
John A. Martignetti, Peter Dottino, Morten Mau-Sørensen, Mansoor R. Mirza, Michael Kauffman, Tami Rashal, Yosef Landesman, Dilara McCauley, Sharon Shacham, Jean-Noel Billaud, Richard Halpert, Rileen Sinha, Rong Chen, Andrew Uzilov, Robert Sebra, Tamara Kalir, Faisal Khan, Michael Donovan, Estefania Rodriguez, Nolan Priedigkeit, Fei Huang, Susan J. Ramus, Brad R. Evans, Elena Pereira, Eva Kalir, John F. Gerecitano, Nashat Y. Gabrail, Albiruni R.A. Razak, Thomas R. Silvers, Sandra Catalina Camacho, Ying Chen
Supplementary Material and Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd94388a9ace123fadf893e903e3182
https://doi.org/10.1158/1078-0432.22464165.v1
https://doi.org/10.1158/1078-0432.22464165.v1
Autor:
David S. Hong, Albiruni R.A. Razak, Lillian L. Siu, Funda Meric-Bernstam, Alona Zer, Denis L.F. Jardim, Kenneth Hess, Diogo D.G. Bugano
Drugs Approved by the U.S. Food and Drug Administration by April 30, 2014, That Were Included in the Analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8cd3716e29f6c23d1879c8242890515
https://doi.org/10.1158/1078-0432.22467939
https://doi.org/10.1158/1078-0432.22467939
Autor:
David S. Hong, Albiruni R.A. Razak, Lillian L. Siu, Funda Meric-Bernstam, Alona Zer, Denis L.F. Jardim, Kenneth Hess, Diogo D.G. Bugano
Purpose: Evaluate the association between the use of phase I expansion cohorts (ECs) and drug performance in phase II as well as time to approval by the FDA.Experimental Design: We performed a systematic search of MEDLINE for single-agent dose-findin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08cfdefe239030c0c840900533a23a56
https://doi.org/10.1158/1078-0432.c.6526794.v1
https://doi.org/10.1158/1078-0432.c.6526794.v1
Autor:
John A. Martignetti, Peter Dottino, Morten Mau-Sørensen, Mansoor R. Mirza, Michael Kauffman, Tami Rashal, Yosef Landesman, Dilara McCauley, Sharon Shacham, Jean-Noel Billaud, Richard Halpert, Rileen Sinha, Rong Chen, Andrew Uzilov, Robert Sebra, Tamara Kalir, Faisal Khan, Michael Donovan, Estefania Rodriguez, Nolan Priedigkeit, Fei Huang, Susan J. Ramus, Brad R. Evans, Elena Pereira, Eva Kalir, John F. Gerecitano, Nashat Y. Gabrail, Albiruni R.A. Razak, Thomas R. Silvers, Sandra Catalina Camacho, Ying Chen
Supplementary Figure 1. Overview of XPO1's role in nuclear:cytoplasmic transport. Supplementary Figure 2. KPT-185 is much less toxic to patient-derived benign cells than patient-derived serous high grade OvCa cells. Supplementary Figure 3. FACS cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bda5ace0e09d7253667d7c8ae0026f8
https://doi.org/10.1158/1078-0432.22464168
https://doi.org/10.1158/1078-0432.22464168
Autor:
John A. Martignetti, Peter Dottino, Morten Mau-Sørensen, Mansoor R. Mirza, Michael Kauffman, Tami Rashal, Yosef Landesman, Dilara McCauley, Sharon Shacham, Jean-Noel Billaud, Richard Halpert, Rileen Sinha, Rong Chen, Andrew Uzilov, Robert Sebra, Tamara Kalir, Faisal Khan, Michael Donovan, Estefania Rodriguez, Nolan Priedigkeit, Fei Huang, Susan J. Ramus, Brad R. Evans, Elena Pereira, Eva Kalir, John F. Gerecitano, Nashat Y. Gabrail, Albiruni R.A. Razak, Thomas R. Silvers, Sandra Catalina Camacho, Ying Chen
Purpose: The high fatality-to-case ratio of ovarian cancer is directly related to platinum resistance. Exportin-1 (XPO1) is a nuclear exporter that mediates nuclear export of multiple tumor suppressors. We investigated possible clinicopathologic corr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0145a7f4193fe36b646da6771fbef93b
https://doi.org/10.1158/1078-0432.c.6525636.v1
https://doi.org/10.1158/1078-0432.c.6525636.v1
Autor:
John A. Martignetti, Peter Dottino, Morten Mau-Sørensen, Mansoor R. Mirza, Michael Kauffman, Tami Rashal, Yosef Landesman, Dilara McCauley, Sharon Shacham, Jean-Noel Billaud, Richard Halpert, Rileen Sinha, Rong Chen, Andrew Uzilov, Robert Sebra, Tamara Kalir, Faisal Khan, Michael Donovan, Estefania Rodriguez, Nolan Priedigkeit, Fei Huang, Susan J. Ramus, Brad R. Evans, Elena Pereira, Eva Kalir, John F. Gerecitano, Nashat Y. Gabrail, Albiruni R.A. Razak, Thomas R. Silvers, Sandra Catalina Camacho, Ying Chen
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37be2227d7e7d5b4425f5fb0ff89b03d
https://doi.org/10.1158/1078-0432.22464174.v1
https://doi.org/10.1158/1078-0432.22464174.v1
Autor:
John A. Martignetti, Peter Dottino, Morten Mau-Sørensen, Mansoor R. Mirza, Michael Kauffman, Tami Rashal, Yosef Landesman, Dilara McCauley, Sharon Shacham, Jean-Noel Billaud, Richard Halpert, Rileen Sinha, Rong Chen, Andrew Uzilov, Robert Sebra, Tamara Kalir, Faisal Khan, Michael Donovan, Estefania Rodriguez, Nolan Priedigkeit, Fei Huang, Susan J. Ramus, Brad R. Evans, Elena Pereira, Eva Kalir, John F. Gerecitano, Nashat Y. Gabrail, Albiruni R.A. Razak, Thomas R. Silvers, Sandra Catalina Camacho, Ying Chen
Supplementary Table 1. cBIO data for XPO1 overexpression and association with survival. Supplementary Table 2. Clinical features of patient samples in TMA. Supplementary Table 3. Clinicopathologic features for patient-derived tumor cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bda1421f88aa036542b3c59734051f3
https://doi.org/10.1158/1078-0432.22464162.v1
https://doi.org/10.1158/1078-0432.22464162.v1
Autor:
Silvia Stacchiotti, Anna Maria Frezza, George D. Demetri, Jean-Yves Blay, Jyoti Bajpai, Giacomo G. Baldi, Elizabeth H. Baldini, Robert S. Benjamin, Sylvie Bonvalot, Judith V.M.G. Bovée, Dario Callegaro, Paolo G. Casali, Sandra P. D'Angelo, Elizabeth J. Davis, Angelo P. Dei Tos, Elizabeth G. Demicco, Jayesh Desai, Palma Dileo, Mikael Eriksson, Hans Gelderblom, Suzanne George, Rebecca A. Gladdy, Mrinal M. Gounder, Abha A. Gupta, Rick Haas, Andrea Hayes, Peter Hohenberger, Kevin B. Jones, Robin L. Jones, Bernd Kasper, Akira Kawai, David G. Kirsch, Eugenie S. Kleinerman, Axel Le Cesne, Roberta Maestro, Javier Martin Broto, Robert G. Maki, Aisha B. Miah, Emanuela Palmerini, Shreaskumar R. Patel, Chandrajit P. Raut, Albiruni R.A. Razak, Damon R. Reed, Piotr Rutkowski, Roberta G. Sanfilippo, Marta Sbaraglia, Inga-Marie Schaefer, Dirk C. Strauss, Sandra J. Strauss, William D. Tap, David M. Thomas, Annalisa Trama, Jonathan C. Trent, Winette T.A. van der Graaf, Winan J. van Houdt, Margaret von Mehren, Breelyn A. Wilky, Christopher D.M. Fletcher, Alessandro Gronchi, Rosalba Miceli, Andrew J. Wagner
Publikováno v:
Cancer Treatment Reviews, 110. ELSEVIER SCI LTD
Background: In ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to poor acceptance b